MedTrace Logo

Effectiveness Of Radiofrequency Ablation And Stabilization In Metastatic Spine Lesions By Positron Emission Computed Tomography (PET-CT) Confirmation

NCT06716294 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2026-04-09

No results posted yet for this study

Summary

This pilot study will try to demonstrate metabolic changes in spine lesions treated by Augmentation and Ablation, according to existing standards of practice. Our purpose is to show the efficacy of a new radiofrequency ablation (RFA) in combination with augmentation, using a percutaneous ablation device (Osteocool-Medtronic) in the treatment of secondary vertebral bone tumor, avoiding concurrent bias related to other treatments of the disease.

Conditions

  • Bone Cancer Metastatic
  • Radiofrequency Ablation
  • Spine Metastases
  • Vertebral Metastasis

Interventions

DEVICE

Radiofrequency Ablation and Bone Augmentation

Percutaneous Tumor Ablation of Spine Lesions followed by Polymer Augmentation

Sponsors & Collaborators

  • National and Kapodistrian University of Athens

    lead OTHER

Principal Investigators

  • ALEXIOS KELEKIS, MD, PHD · National and Kapodistrian University of Athens

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2028-06-01
Completion
2028-12-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06716294 on ClinicalTrials.gov